Zobrazeno 1 - 10
of 172
pro vyhledávání: '"Marta, Brambilla"'
Autor:
Barbara Bassani, Giorgia Simonetti, Valeria Cancila, Antonio Fiorino, Marilena Ciciarello, Annamaria Piva, Arman Mandegar Khorasani, Claudia Chiodoni, Daniele Lecis, Alessandro Gulino, Eugenio Fonzi, Laura Botti, Paola Portararo, Massimo Costanza, Marta Brambilla, Giorgia Colombo, Juerg Schwaller, Alexandar Tzankov, Maurilio Ponzoni, Fabio Ciceri, Niccolò Bolli, Antonio Curti, Claudio Tripodo, Mario P. Colombo, Sabina Sangaletti
Publikováno v:
Cell Reports, Vol 43, Iss 2, Pp 113794- (2024)
Summary: Acute myeloid leukemia (AML) progression is influenced by immune suppression induced by leukemia cells. ZEB1, a critical transcription factor in epithelial-to-mesenchymal transition, demonstrates immune regulatory functions in AML. Silencing
Externí odkaz:
https://doaj.org/article/da7ae959a4304ef9b858b1b572ed0a44
Autor:
Filippo de Braud, Valter Torri, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Monica Ganzinelli, Marina Chiara Garassino, Giuseppe Viscardi, Giorgio Trinchieri, Mario Occhipinti, Rita Leporati, Marta Brambilla, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Andrea Anichini, Leonardo Provenzano, Daniele Lorenzini, Arsela Prelaj, James Dolezal, Teresa Beninato, Tiziana Triulzi, Alessandra Fabbri, Laura Mazzeo, Andrea Spagnoletti, Vanja Miskovic, Alessandra Laura Giulia Pedrocchi, Francesco Trovo', Sara Manglaviti, Claudia Giani, Paolo Ambrosini, Andrea Franza, John McCulloch, Tommaso Torelli, Giancarlo Pruneri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1)
Externí odkaz:
https://doaj.org/article/0391ecab2ee246659837c5b760a7cc74
Autor:
Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios
Publikováno v:
Drugs in Context, Vol 11, Pp 1-10 (2022)
EGFR exon 20 insertion mutations (Ex20ins) and HER2 mutations characterize an oncogene-addicted subtype of non-small-cell lung cancer (NSCLC) typically associated with a never or light smoking history, female sex, and adenocarcinoma histology. Nevert
Externí odkaz:
https://doaj.org/article/7f25efcbc0634ca08522dde133c6dc91
Autor:
Andrea De Giglio, Alessandro Di Federico, Chiara Deiana, Biagio Ricciuti, Marta Brambilla, Giulio Metro
Publikováno v:
Drugs in Context, Vol 11, Pp 1-14 (2022)
The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, h
Externí odkaz:
https://doaj.org/article/226e6327ae56488194bc82ab8bbb8310
Autor:
Marta Brambilla, Roberto Frigerio, Alessia Becchetti, Alessandro Gori, Marina Cretich, Maria Conti, Antonella Mazza, Martino Pengo, Marina Camera
Publikováno v:
Biology, Vol 12, Iss 9, p 1233 (2023)
The relative contribution of small (sEVs) and large extracellular vesicles (lEVs) to the total plasma procoagulant potential is not yet well defined. Thus, we compared total and TFpos-sEVs and -lEVs isolated from healthy subjects and COVID-19 patient
Externí odkaz:
https://doaj.org/article/17347c41dcac4e0fab19c31ebdba1ef9
Publikováno v:
Platelets, Vol 33, Iss 2, Pp 192-199 (2022)
Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activa
Externí odkaz:
https://doaj.org/article/6e80eefa8e044f41aa28fbc2c8b9ed3a
Autor:
Arsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, Mattia Pesenti, Giuseppe Viscardi, Benedetta Pedica, Laura Mazzeo, Achille Bottiglieri, Leonardo Provenzano, Andrea Spagnoletti, Roberto Marinacci, Alessandro De Toma, Claudia Proto, Roberto Ferrara, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Giulia Galli, Diego Signorelli, Claudia Giani, Teresa Beninato, Chiara Carlotta Pircher, Alessandro Rametta, Sokol Kosta, Michele Zanitti, Maria Rosa Di Mauro, Arturo Rinaldi, Settimio Di Gregorio, Martinetti Antonia, Marina Chiara Garassino, Filippo G. M. de Braud, Marcello Restelli, Giuseppe Lo Russo, Monica Ganzinelli, Francesco Trovò, Alessandra Laura Giulia Pedrocchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionArtificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed a model to predict the efficacy of immunotherapy (IO) in pa
Externí odkaz:
https://doaj.org/article/c99b6a5fcaed44e39c58687c3976c7f5
Autor:
Filippo de Braud, Alessandra Raimondi, Salvatore Provenzano, Marta Brambilla, Cinzia Brunelli, Monica Niger, Ernesto Zecca, Paola Bracchi, Silvia Lo Dico, Mariangela Caputo, Alessandra Pigni, Viviana Fusetti, Antonino Tallarita, Cristiana Bergamini, Pierangela Sepe, Sara Alfieri, Gabriele Tinè, Augusto Tommaso Caraceni
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Introduction Early palliative care (PC) in the clinical pathway of advanced cancer patients improves symptom control, quality of life and has a positive impact on overall quality of care. At present, standardised criteria for appropriate referral for
Externí odkaz:
https://doaj.org/article/a33707cf3af04e4eae1483693edef846
Autor:
Diego Signorelli, Patrizia Ghidotti, Claudia Proto, Marta Brambilla, Alessandro De Toma, Roberto Ferrara, Giulia Galli, Monica Ganzinelli, Giuseppe Lo Russo, Arsela Prelaj, Mario Occhipinti, Giuseppe Viscardi, Valentina Capizzuto, Francesca Pontis, Ilaria Petraroia, Anna Maria Ferretti, Mario Paolo Colombo, Valter Torri, Gabriella Sozzi, Marina Chiara Garassino, Elena Jachetti, Orazio Fortunato
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter is inaccurate to predict response, especially in patients with low tumor PD
Externí odkaz:
https://doaj.org/article/ab5e8307dc3647979bd096212900848c
Autor:
Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, Rocky Washington, Giuseppina Calareso, Gabriella Francesca Greco, Roberto Ferrara, Marta Brambilla, Alessandro De Toma, Mario Occhipinti, Sara Manglaviti, Alberto Soro, Monica Ganzinelli, Giuseppe Lo Russo, Claudia Proto
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20,
Externí odkaz:
https://doaj.org/article/737d107e33f34e698cd951a3dca78457